Find Funding Opportunities

The purpose of this time-sensitive Request for Information (RFI) is to seek input from scientists, clinicians, patients, families, caregivers, advocates, and the broader dementia community on the most important needs and promising opportunities for Alzheimer's disease-related dementias (ADRD) research. The information submitted in response to this RFI will be used by committees of scientists, clinicians, and other members of the public to revise and update the ADRD 2019 research recommendations.

The National Institute for Neurological Disorders and Stroke (NINDS) is interested in applications that fall within the NINDS mission space: https://www.ninds.nih.gov/about-ninds/what-we-do/ninds-mission. Applicants are strongly encouraged to confirm NINDS mission fit with the NINDS Small Business Program prior to submission.

Changing first receipt date.

This NOFO solicits applications for next generation sensor and bioelectronic device development that will synchronize with brain recordings. The sensor and neural recording data will be used to generate new computational models of behavior in human and animal models. There has been a lack of quantitative approaches and models to understand the complexity of human and animal behavior in naturalistic settings. This NOFO focuses on the development of next generation sensors to acquire data and synchronize it with simultaneous brain recordings to build computational models.

Please join us for a preapplication technical assistance webinar to discuss RFA-NS-24-041 NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional). This RFA will support applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. The purpose of this webinar is to provide potential grant applicants with an overview of the RFA and address questions from the scientific community. The webinar will feature highlights of application considerations from program staff at National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Complementary and Integrative Health (NCCIH). It will also include a presentation on review requirements from NCCIHs Office of Scientific Review.

This Notice of Special Interest (NOSI) is to solicit applications to support a series of annual scientific meetings for the Chemical Countermeasures Research Program (CCRP).

This announcement supports Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and mouse. Projects validating approaches using other species are also permitted if well justified. Applications may address any aspects of the data collection, analysis, and dissemination pipelines, to enable faster and more cost-effective generation and interpretation of brain-wide wiring diagrams. Projects will offer distinct capabilities and competencies aimed at developing and optimizing current technologies or entirely new and potentially risky approaches. They will be integrated into the BRAIN CONNECTS Network, consisting of other Specialized Projects from this FOA, and Comprehensive Centers from its companion announcements, as a coordinated effort aimed at developing wiring diagrams that can span entire brains across multiple scales.

Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Postural Orthostatic Tachycardia Syndrome (POTS) is a debilitating condition that affects between 0.2 and 1% of the US population and may be even more prevalent since the COVID-19 pandemic. The conditionimpairs individuals' ability to participate in routine activities such as working, attending school, exercising and activities of daily life. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. While many individuals with POTS report symptoms beginning in adolescence, up to half of all individuals with POTS develop it in adulthood. The impact of POTS across the lifespan has until now not been well studied, and given the female preponderance of the condition there is an unmet need to study how the condition is impacted by events such as menarche, pregnancy and menopause. There is a compelling need to stimulate research focused on improving diagnosis and treatment of POTS. This may include development of biomarkers and diagnostic tools as well as translational studies and mechanistic clinical trials to guide the development of interventions aimed at preventing and curing POTS. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs.